| Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study. | |
| | |
MedLine Citation:
|
PMID: 18937609 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To assess the effect of rimonabant, micronised fenofibrate and their combination on anthropometric and metabolic parameters in overweight/obese patients with dyslipidaemia. METHODS: All patients (n = 30) received a hypocaloric diet ( approximately 600 kcal/day deficit) and were randomly allocated to receive open-label rimonabant (R) 20 mg/day (n = 10), micronised fenofibrate (F) 200 mg/day (n = 10) or rimonabant 20 mg/day plus fenofibrate 200 mg/day (RF) (n = 10). Anthropometric and metabolic parameters were assessed at baseline and 3 months after treatment initiation. RESULTS: Compared with baseline similar significant reductions in body weight, body mass index and waist circumference were observed in the R (-6, -5 and -5%, respectively; p < 0.01) and RF group (-5% for all, p < 0.05), while improvements in these parameters were smaller in the F group (-2, -2.5 and -2%, respectively; p < 0.05). Triglycerides were reduced by 18% in the R group (p = NS), by 39% in the F group (p < 0.001) and by 46% in the RF group (p < 0.05). Importantly, combination treatment resulted in a 42% increase in high-density lipoprotein cholesterol (HDL-C) levels (p < 0.05), while HDL-C was not significantly altered in the two monotherapy groups. Subsequently, a more pronounced increase in apolipoprotein A-I (ApoA-I) levels (+25%) was observed in the RF group compared with changes in both monotherapy groups (p < 0.0001 vs R and p < 0.005 vs F group). Low-density lipoprotein cholesterol (LDL-C) levels were not significantly altered in any group. Apolipoprotein B (apoB) levels were reduced in all groups and this reduction was significantly more pronounced in the RF group (p < 0.05 vs baseline as well as p < 0.005 and p < 0.01 for RF vs R and F groups, respectively). ApoB/apoA-I ratio decreased by 3% with R (p = NS), by 18% with F (p < 0.05) and by 40% with RF treatment (p < 0.01). Total cholesterol to HDL-C ratio decreased by 20% with F (p < 0.0001) and by 33% with RF therapy (p < 0.005), while it was not significantly altered in R group. CONCLUSION: The combination of rimonabant and fenofibrate may further improve metabolic parameters in overweight/obese patients with dyslipidaemia compared with each monotherapy. This improvement is particularly pronounced for HDL-C levels. |
| | |
Authors:
|
M Florentin; E N Liberopoulos; T D Filippatos; C Kostara; A Tselepis; D P Mikhailidis; M Elisaf |
Related Documents
:
|
6968809 - The effect of portacaval shunt on hyperlipidemia in rats. 7616869 - A comparative study of two hormone replacement therapy regimens on safety and efficacy ... 19819789 - The effects of lowering uric acid levels using allopurinol on markers of metabolic synd... 17027569 - A population-based, cross-sectional comparison of lipid-related indexes for symptoms of... 3902379 - Comparative study of bezafibrate and fenofibrate in patients with primary hyperlipoprot... 2405089 - Metabolic effects of controlled-release metoprolol in hypertensive men with impaired or... 17513399 - Dietary encapsulated glycine influences clostridium perfringens and lactobacilli growth... 15367259 - The effect of intravaginal applied gnrh-agonist on the time of ovulation and subsequent... 19011369 - Eating beyond satiety and body mass index. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: 9 ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2008 Nov |
Date Detail:
|
Created Date: 2008-10-21 Completed Date: 2009-01-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: England |
Other Details:
|
Languages: eng Pagination: 2741-50 Citation Subset: IM |
Affiliation:
|
University of Ioannina, Medical School, Department of Internal Medicine, 45110, Ioannina, Greece. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Blood Pressure
/
drug effects Body Mass Index Body Weight / drug effects Cardiovascular System / drug effects*, metabolism*, pathology Female Heart / drug effects Humans Male Middle Aged Overweight / metabolism* Pilot Projects Piperidines / pharmacology* Procetofen / administration & dosage, pharmacology* Pyrazoles / pharmacology* Risk Factors Time Factors Waist Circumference / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Piperidines; 0/Pyrazoles; 158681-13-1/rimonabant; 49562-28-9/Procetofen |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Patient-controlled versus continuous anesthesiologist-controlled sedation using propofol during regi...
Next Document: Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic ac...